ノバルティスCEO、120億ドルの米バイオ企業買収は「取るべき適切なリスク」

By Bhanvi Satija

ノバルティスCEO、120億ドルの米バイオ企業買収は「取るべき適切なリスク」

Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.

Previous articleNext article

POPULAR CATEGORY

misc

18185

entertainment

20730

corporate

17604

research

10462

wellness

17272

athletics

21678